Who Generates More Revenue? Pharming Group N.V. or Corcept Therapeutics Incorporated

Corcept's Revenue Dominance Over Pharming: A Decade in Review

__timestampCorcept Therapeutics IncorporatedPharming Group N.V.
Wednesday, January 1, 20142655100025762439
Thursday, January 1, 20155028600011838278
Friday, January 1, 20168132100016693660
Sunday, January 1, 2017159201000107517335
Monday, January 1, 2018251247000154575611
Tuesday, January 1, 2019306486000189333721
Wednesday, January 1, 2020353874000228394666
Friday, January 1, 2021365978000189853037
Saturday, January 1, 2022401858000205622000
Sunday, January 1, 2023482375000245316000
Loading chart...

In pursuit of knowledge

Revenue Race: Pharming Group N.V. vs. Corcept Therapeutics

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of success. Over the past decade, Corcept Therapeutics Incorporated has consistently outperformed Pharming Group N.V. in terms of revenue. Starting in 2014, Corcept's revenue was approximately 3% higher than Pharming's. By 2023, this gap widened significantly, with Corcept generating nearly double the revenue of Pharming.

Corcept's revenue growth has been impressive, increasing by over 1,700% from 2014 to 2023. In contrast, Pharming's revenue grew by about 850% during the same period. This trend highlights Corcept's strategic advancements and market positioning. As the pharmaceutical sector continues to evolve, these companies' financial trajectories offer valuable insights into their operational strategies and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025